NPPB and Myocardial fibrosis: Pirfenidone, an anti-fibrotic agent without haemodynamic effect, was associated with a significant reduction in myocardial fibrosis, measured using ECV, and a significant reduction in NT-proBNP, in patients with heart failure with preserved ejection fraction [45].